Seeing Tumor Tissue Under a Better Microscope

For surgeons, the SRS microscope offers speed, safety and efficiency in assessing what is and is not tumor tissue — on the spot.

4:34 PM

Author | Daniel Orringer, M.D.

Where does a brain tumor start and healthy brain tissue begin? This is one of the most challenging questions a brain surgeon faces, because brain tumor tissue can be difficult to distinguish from the rest of the brain.

That's one of many reasons we are testing a new microscope designed to radically change brain tumor surgery, with an eye on both patient safety and better efficiency. So far, we have used the microscope — called the stimulated Raman scattering (SRS) microscope — on tissues from 89 patients with great success.

Two critical factors: timing and location 

On top of the challenge of visually locating the edges of a tumor, we also typically need to wait 30–45 minutes for a frozen tumor section to be created and interpreted using traditional techniques. 

Not so with the SRS microscope. It allows us to detect a tumor in a few seconds.  

Right now, we are using the microscope on an experimental basis through grants from the National Institutes of Health and the University of Michigan Translational Research and Commercialization for Life Sciences Program. We are using the microscope almost exclusively on neurosurgical cases. I'm also collaborating with Matt Spector, M.D., who is a head and neck surgeon, to look at squamous cell carcinoma.  

Our work suggests that surgeons also will be able to use the SRS microscope in breast cancer surgery and for other cancerous tumors. Ultimately, the goal is to use a data-driven, objective approach to determine the exact location of a tumor infiltration instead of relying exclusively on a surgeon's intuition.  

The SRS microscope can tell you on the spot, in the operating room, whether tissue contains a tumor or not.

Daniel Orringer, M.D.

How we achieve speed 

The standard pathology lab workflow used for 150 years requires removing the tumor tissue, then fixing, embedding, staining with dyes and mounting the tissue on slides. 

With the SRS technology, we simply load the tissue onto the SRS microscope and take an image of it. With an SRS microscope, images are created based only on the chemical building blocks that exist in the tissue. There are no other steps — no dyes, no fixation and no sectioning. The images we get are comparable to the images we get with traditional microscopes. The SRS microscope can tell you on the spot, in the operating room, whether tissue contains a tumor or not.  

The SRS technology we are using was originally developed in the laboratory of my collaborator at Harvard, Professor Sunney Xie, and built by a company called Invenio Imaging Inc. 

What comes next 

We are also working on a second-generation SRS microscope that will sit close to the operating table. The goal is for the entire medical team to be able to use and understand the device easily so the images will help determine immediately whether the surgeon needs to remove more tissue. 

We hope to have the machine approved by the FDA within 18 to 24 months. 

For surgeons, we want the SRS to provide precision, efficiency and speed. Ultimately, that means better surgical outcomes for patients. 

Disclosure: Orringer and Xie are advisers and shareholders of Invenio Imaging Inc., a company developing SRS microscopy systems. Their co-author Freudiger is an employee of Invenio Imaging, Inc. 

The University of Michigan, Harvard University and Invenio Imaging have intellectual property used in this research.


More Articles About:

Health Tech Cancer Diagnosis Surgical Oncology Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells

Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

yellow black purple red cell in middle mostly black
Health Lab

Study sheds light on how early pancreas lesions become cancerous

Why many precursor lesions never develop into pancreatic cancer, according to findings from Michigan Medicine.
Cancer Aware surrounded by a circle of multicolor ribbons
Cancer Aware

Cutting edge treatment for advanced colon cancer

Andrew Sweeney, now 35, was aware of his risk for colorectal cancer – his mother had had been diagnosed with it when she was 41. When he was 31, a CT scan at University of Michigan Health’s University Hospital revealed that Sweeney had a mass in his colon and potential metastases in his liver and lymph nodes. A colonoscopy confirmed that he had stage 4 colorectal cancer. After 1.5 years of chemotherapy, his care team began discussing how they could remove the damaged parts of Sweeney’s liver. They developed a colorectal cancer liver transplant protocol from a deceased donor and Sweeney was the first patient to undergo a liver transplant in Michigan for colon cancer. After minor recurrences of tumors in his lung in 2024, which were treated by surgery and radiation, his scans have been clear.
BCI Implant at University of Michigan
News Release

University of Michigan Health opens brain-computer interface clinic, among first in nation

University of Michigan Health has launched a brain-computer interface clinic for patients with motor and speech disabilities. The advanced technology has potential to recover functionality loss that occurs due to injury or disease.
two runners standing next to each other on street in running gear
Health Lab

Pancreatic cancer survivor’s advice: Don’t give up on finding answers

Unexplained abdominal symptoms sidelined an otherwise healthy, active life. After countless failed attempts to find the cause, a chance introduction opened the door to answers and recovery.
Cancer Aware surrounded by a circle of multicolor ribbons
Cancer Aware

University of Michigan’s Impact on the Future of Cancer Care

Four University of Michigan faculty members have served as president of the American Society of Clinical Oncology, a rare distinction that only two other institutions can claim. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. In this episode, Nicole Fawcett, director of communications for the Rogel Cancer Center, sat down with four past ASCO Presidents and talked about the importance of the society, the impact it has had on cancer care and research as a whole and the impact here at U-M. Participants: Allen Lichter, MD, FASTRO Doug Blayney, MD Dan Hayes, MD Lori Pierce, MD
three friends standing outside rogel cancer center building with big white ribbons
Health Lab

A lung cancer survivor shaping lung cancer advocacy

One woman's unexpected lung cancer diagnosis leads her to help many who aren't aware they're at risk of the disease.